AU2017224122B2 - Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof - Google Patents

Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof Download PDF

Info

Publication number
AU2017224122B2
AU2017224122B2 AU2017224122A AU2017224122A AU2017224122B2 AU 2017224122 B2 AU2017224122 B2 AU 2017224122B2 AU 2017224122 A AU2017224122 A AU 2017224122A AU 2017224122 A AU2017224122 A AU 2017224122A AU 2017224122 B2 AU2017224122 B2 AU 2017224122B2
Authority
AU
Australia
Prior art keywords
antibody
seq
sequence
ser
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017224122A
Other languages
English (en)
Other versions
AU2017224122A1 (en
Inventor
Zhiqiang An
Sumin GU
Jean X. Jiang
Manuel A. Riquelme
Naomi Ledene Sayre
Wei Xiong
Ningyan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2017224122A1 publication Critical patent/AU2017224122A1/en
Application granted granted Critical
Publication of AU2017224122B2 publication Critical patent/AU2017224122B2/en
Priority to AU2024204761A priority Critical patent/AU2024204761A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017224122A 2016-02-26 2017-02-27 Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof Active AU2017224122B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024204761A AU2024204761A1 (en) 2016-02-26 2024-07-10 Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662300492P 2016-02-26 2016-02-26
US62/300,492 2016-02-26
PCT/US2017/019605 WO2017147561A1 (en) 2016-02-26 2017-02-27 CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024204761A Division AU2024204761A1 (en) 2016-02-26 2024-07-10 Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof

Publications (2)

Publication Number Publication Date
AU2017224122A1 AU2017224122A1 (en) 2018-09-20
AU2017224122B2 true AU2017224122B2 (en) 2024-04-11

Family

ID=59685694

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017224122A Active AU2017224122B2 (en) 2016-02-26 2017-02-27 Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
AU2024204761A Pending AU2024204761A1 (en) 2016-02-26 2024-07-10 Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024204761A Pending AU2024204761A1 (en) 2016-02-26 2024-07-10 Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof

Country Status (7)

Country Link
US (2) US10889637B2 (enExample)
EP (1) EP3419998A4 (enExample)
JP (1) JP7098527B2 (enExample)
CN (2) CN116672445A (enExample)
AU (2) AU2017224122B2 (enExample)
CA (1) CA3015839A1 (enExample)
WO (1) WO2017147561A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12503500B2 (en) 2024-02-09 2025-12-23 Board Of Regents, The University Of Texas System Connexin 43 (Cx43) hemichannel-binding antibodies

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3036005A4 (en) 2013-08-21 2017-04-26 The Board Of Regents Of The University Of Texas System Compositions and methods for targeting connexin hemichannels
WO2017147561A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF
ES2710220A1 (es) * 2017-10-19 2019-04-23 Fund Profesor Novoa Santos Compuestos anti-conexina para su uso en la prevención y/o el tratamiento de enfermedades degenerativas de las articulaciones
AU2019249427A1 (en) * 2018-04-02 2020-10-29 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
WO2019222800A1 (en) * 2018-05-21 2019-11-28 Hudson Institute of Medical Research Methods for the treatment or prevention of autoimmune or autoinflammatory diseases
US12187794B2 (en) * 2019-02-04 2025-01-07 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
JP7710374B2 (ja) * 2019-02-28 2025-07-18 ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム 骨肉腫を治療するための組成物及び使用方法
AU2020358101A1 (en) 2019-10-02 2022-04-28 Alamab Therapeutics, Inc. Anto-connexin antibody formulations
WO2022026914A1 (en) * 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
EP3981421A1 (en) * 2020-10-06 2022-04-13 Fundación Profesor Novoa Santos Connexin 43 for use in the treatment of a cancer type characterized by the activation of a mitogen-activated protein kinase
CN117377686A (zh) * 2021-01-13 2024-01-09 德克萨斯大学体系董事会 用于治疗骨关节炎、类风湿性关节炎以及关节和肌腱病症的组合物和方法
WO2023212727A1 (en) * 2022-04-29 2023-11-02 Board Of Regents, The University Of Texas System Compositions and methods for treating eye diseases
JP2025515029A (ja) * 2022-05-04 2025-05-13 ブイエスティー バイオ コーポレーション 血管透過性の選択的調節のための組成物及び方法
WO2024145461A2 (en) * 2022-12-30 2024-07-04 Board Of Regents, The University Of Texas System Compositions for treating osteoporosis and bone loss and methods of use thereof
WO2024206157A1 (en) * 2023-03-24 2024-10-03 Board Of Regents, The University Of Texas System Compositions and methods for treating obesity and reducing fat accumulation
WO2025199516A1 (en) * 2024-03-22 2025-09-25 Board Of Regents, The University Of Texas System Compositions and methods for preserving or increasing lean muscle mass
CN118791620B (zh) * 2024-07-02 2025-04-04 北京市华信行生物科技有限公司 抗糖原磷酸化酶gpbb单克隆抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015027120A1 (en) * 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4606855A (en) 1982-07-26 1986-08-19 Mex Research Associates C/O Leon Reimer Monoclonal antibody to digoxin
US4469797A (en) 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3330160A1 (de) 1983-08-20 1985-03-07 Boehringer Ingelheim KG, 6507 Ingelheim Monoklonaler antikoerper mit hoher affinitaet zum digoxin
DE3342870A1 (de) 1983-11-26 1985-06-05 Boehringer Mannheim Gmbh, 6800 Mannheim Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen
US4767720A (en) 1985-08-29 1988-08-30 Hsc Research Development Corporation Antidigoxin antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5164296A (en) 1990-08-31 1992-11-17 University Of Maryland At Baltimore Assay methods involving ouabain
US5656434A (en) 1990-12-28 1997-08-12 Suntory Limited Monoclonal antibody against cardiac glycoside and utilization thereof
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5770376A (en) 1992-12-02 1998-06-23 Biomedical Sciences Research Laboratories, Inc. Method of diagnosing and treating myocardial infarction and hypertension
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5420253A (en) 1993-09-09 1995-05-30 Willmar Poultry Company, Inc. Method for purifying egg yolk immunoglobulins
GB9325182D0 (en) 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
DK1231268T3 (da) 1994-01-31 2005-11-21 Univ Boston Polyklonale antistofbiblioteker
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US6709659B1 (en) 1996-08-02 2004-03-23 Zymogenetics, Inc. Antibodies that bind testis-specific insulin homolog polypeptides
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
US6709873B1 (en) 1997-04-09 2004-03-23 Isodiagnostika Inc. Method for production of antibodies to specific sites of rapamycin
US6861572B1 (en) 1997-11-14 2005-03-01 Origen Therapeutics, Inc. Production of proteins in eggs
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
HUP0102782A3 (en) 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
US6432673B1 (en) 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
PT1146908E (pt) * 1999-01-27 2005-10-31 David Dr Becker Formulacoes que contem nucleotidos de anti-sentido para conexinas
US20020064528A1 (en) 2000-01-28 2002-05-30 Zhenping Zhu Antibodies specific to KDR and uses thereof
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6753407B2 (en) 2000-08-15 2004-06-22 North Carolina State University Antimicrobial peptides isolated from fish
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US6891024B2 (en) 2001-05-24 2005-05-10 The Curators Of The University Of Missouri Monoclonal antibodies to Sarcocystis neurona and uses therefor
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US6906131B2 (en) 2001-09-17 2005-06-14 Stockhausen Gmbh & Co. Kg Cellulose material with improved absorbency
US7153822B2 (en) 2002-01-29 2006-12-26 Wyeth Compositions and methods for modulating connexin hemichannels
KR101215701B1 (ko) 2002-07-19 2012-12-26 베스 이스라엘 데코니스 메디칼 센터 자간전증 또는 자간의 진단 및 치료 방법
AU2004294824A1 (en) 2003-12-03 2005-06-16 Coda Therapeutics (Nz) Ltd Antisense compounds targeted to connexins and methods of use thereof
WO2005085423A1 (en) 2004-02-27 2005-09-15 Michigan State University Oct-4 and gjic expression as markers for adult human stem cells and cancer cell precursors
EP1753880A4 (en) 2004-05-14 2010-07-14 Univ California METHOD FOR THE TREATMENT OF CANCER USING MONOCLONAL ANTI-WNT2 ANTIBODIES AND siRNA
CA2596412A1 (en) 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
CA2710382A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of orthopedic conditions
KR101745394B1 (ko) 2008-12-22 2017-06-09 노보 노르디스크 에이/에스 조직 인자 경로 억제자에 대한 항체
RU2408728C1 (ru) 2009-07-28 2011-01-10 Федеральное государственное учреждение "Государственный Научный Центр Социальной и Судебной Психиатрии им. В.П. Сербского" (ФГУ "ГНЦССП Росздрава") Способ получения иммуногенного рекомбинантного экстраклеточного фрагмента коннексина-43
EP2700652B1 (en) 2011-04-18 2018-12-19 The University of Tokyo Diagnosis and treatment of cancer using anti-itm2a antibody
RU2457862C1 (ru) 2011-07-07 2012-08-10 Федеральное государственное учреждение "Государственный научный центр социальной и судебной психиатрии им. В.П. Сербского" Министерства здравоохранения и социального развития Российской Федерации Способ лечения низкодифференцированных глиом
WO2013163423A1 (en) 2012-04-25 2013-10-31 Musc Foundation For Research Development Compositions and methods for wound healing and tissue repair
WO2017147561A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015027120A1 (en) * 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Yusubalieva, G. et al., 'Antitumor Effects of Monoclonal Antibodies to Connexin 43 Extracellular Fragment in Induced Low-Differentiated Glioma' Translated from Kletochnye Tekhnologii v Biologii i Meditsine, (2012-05-01), pages 51 - 57. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12503500B2 (en) 2024-02-09 2025-12-23 Board Of Regents, The University Of Texas System Connexin 43 (Cx43) hemichannel-binding antibodies

Also Published As

Publication number Publication date
US20190359696A1 (en) 2019-11-28
CA3015839A1 (en) 2017-08-31
JP7098527B2 (ja) 2022-07-11
US20240254212A1 (en) 2024-08-01
AU2017224122A1 (en) 2018-09-20
EP3419998A4 (en) 2019-09-25
CN109071642B (zh) 2022-08-09
WO2017147561A1 (en) 2017-08-31
AU2024204761A1 (en) 2024-08-01
EP3419998A1 (en) 2019-01-02
US10889637B2 (en) 2021-01-12
US11912758B2 (en) 2024-02-27
US20210253680A1 (en) 2021-08-19
CN109071642A (zh) 2018-12-21
JP2019509283A (ja) 2019-04-04
CN116672445A (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
AU2017224122B2 (en) Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
EP4635516A2 (en) Anti-edb antibodies and antibody-drug conjugates
AU2017214685B2 (en) EGFL6 specific monoclonal antibodies and methods of their use
US12503500B2 (en) Connexin 43 (Cx43) hemichannel-binding antibodies
AU2013334583B2 (en) JAM-C antibodies and methods for treatment of cancer
JP7710374B2 (ja) 骨肉腫を治療するための組成物及び使用方法
US20250277037A1 (en) Antibodies specific to pd-1 and methods of use
HK40062936B (zh) 用於治疗骨肉瘤的组合物和使用方法
HK40062936A (en) Compositions for treating osteosarcoma and methods of use
US20230092390A1 (en) Human 4-1bb agonist antibodies and methods of use thereof
HK1262261B (en) Connexin (cx) 43 hemichannel-binding antibodies and uses thereof
HK1262261A1 (en) Connexin (cx) 43 hemichannel-binding antibodies and uses thereof
WO2025090760A1 (en) Antibodies specific to scube3 and methods of use
HK40012788B (en) Anti-edb antibodies and antibody-drug conjugates
HK40004147B (zh) 高亲和力b7-h6抗体和抗体片段

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)